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Abstract
Growing epidemiological evidence suggests that nonalcoholic fatty liver disease (NAFLD) is an early predictor of and determinant for the development of type 2 diabetes and other features of the metabolic syndrome. This finding may have important clinical implications for the diagnosis, prevention and treatment of type 2 diabetes and its chronic complications. However, given the complex and bi-directional relationships between NAFLD, insulin resistance and chronic hyperglycaemia, it is extremely difficult to distinguish whether NAFLD is a cause or a consequence of insulin resistance and type 2 diabetes. Indeed, at the molecular level, hepatic lipogenesis and hepatic glucose production depend on differentially regulated branches of the insulin signalling pathway. Furthermore, genetic studies suggest that excess hepatic fat is associated with progressive liver disease, but does not always increase the risk of incident type 2 diabetes. Here, we will briefly review the epidemiological, pathophysiological and molecular evidence linking NAFLD to the development of type 2 diabetes. We will also discuss some recent genetic and therapeutic advances that seem to challenge a causal role of NAFLD in the pathogenesis type 2 diabetes, and propose a working hypothesis to explain this apparent conundrum. In conclusion, progressive liver disease and type 2 diabetes are divergent though inter-related consequences of insulin resistance and the metabolic syndrome.




Nonalcoholic fatty liver disease (NAFLD) is defined by excessive hepatic fat content (HFC; >5% of liver weight, mainly in the form of triglycerides) in the absence of excessive alcohol consumption and other competing etiologies for hepatic steatosis. Paralleling the epidemic of obesity in both developed and developing countries, NAFLD has become the leading cause of liver disease, and an emerging important cause of liver failure and hepatocellular carcinoma (1–3). The prevalence of NAFLD increases in subjects with obesity, the metabolic syndrome (MetS), or type 2 diabetes mellitus (T2DM) (4–6). For many years, NAFLD has indeed been considered the hepatic
manifestation of systemic insulin resistance (IR) and the MetS (7, 8). Furthermore, IR and T2DM are among the strongest predictors of the progression of NAFLD to advanced fibrosis and cirrhosis (9–11), while insulin-sensitizing drugs have been used albeit with a variable success for NAFLD treatment (12). However, NAFLD is now increasingly diagnosed also in individuals who do not have T2DM or MetS. This supports the assertion that the conventional paradigm of NAFLD representing the simple ‘hepatic manifestation’ of the MetS is outdated.
Several epidemiological studies have recently suggested that NAFLD may be an early predictor of and a potentially important determinant for the development of both T2DM and other MetS traits (13). This finding may have important clinical implications for the diagnosis, prevention and treatment of T2DM. However, given the complex and bi-directional relationships between NAFLD, IR and T2DM, it is extremely difficult to distinguish whether NAFLD plays a causal role in the
development of T2DM or whether it is merely a consequence of IR/T2DM.
Here, we will review the epidemiological, pathophysiological and molecular evidence linking NAFLD to T2DM development. We will also discuss recent genetic and therapeutic advances that seem to challenge a casual role of NAFLD in T2DM development, and propose a working hypothesis to explain this apparent conundrum. Insulin resistance in NAFLD Insulin resistance is a multifaceted syndrome that expresses itself in many ways, mainly represented by the features of the MetS but not limited to them (13, 14). The physiological effect of insulin varies dramatically from tissue to tissue, and different pathways within the same tissue vary in their degree of IR. Therefore, the complex inter-relationship among NAFLD, IR and MetS cannot be easily detangled.
The most common cause of NAFLD in developed countries is an increased caloric intake exceeding the rates of caloric expenditure, with consequent spillover of extra-energy in the form of lipid precursors (i.e. nonesterified fatty acids, NEFA) from adipose tissue into ectopic depots: liver, visceral fat (VF), skeletal muscle and pancreas (15). Insulin decreases circulating lipids through inhibition of adipose tissue lipolysis and by directly suppressing hepatic production of very low density lipoproteins (VLDL), but in IR states these actions are impaired (14). Specifically, NAFLD develops when the rate of hepatic triglyceride (TG) synthesis, mainly due to increased hepatic NEFA uptake and de novo lipogenesis (DNL) exceeds the rate of hepatic TG catabolism due to NEFA oxidation and TG export as VLDL particles (13). In this sense, NAFLD is promoted by adipose tissue and skeletal muscle IR, and represents a good marker of the severity of IR itself. However, the liver is also a key site of insulin action: it is the main source of endogenous glucose production, a major site for the synthesis and disposal of lipids and the primary site of insulin extraction from plasma. In the liver, which normally extracts circulating NEFA with high efficiency (25–40%), impaired suppression of lipolysis by insulin provides the energy and biochemical signals
required for the stimulation of gluconeogenesis (16). In non-diabetic individuals, increased gluconeogenesis forms the basis of hepatic IR, i.e. rate of hepatic glucose production (HGP) that is inappropriately elevated for the prevailing insulin levels (17, 18). Furthermore, increased HFC and diacylglycerol (DAG) accumulation are associated with decreased insulin-stimulated tyrosine
phosphorylation of both Insulin Receptor Substrate (IRS)-1 and IRS-2 (15), but the causal link between hepatic DAG and IR remains controversial (19). Fasting hyperglycaemia and hyperinsulinaemia are closely associated with both HFC and IR, irrespective of body mass index (20). Evaluation of the main sites of IR by the euglycaemic hyperinsulinaemic clamp studies, coupled with tracers infusion in a group of non-diabetic nonobese patients with NAFLD, revealed the presence of IR in the following target pathways: endogenous insulin  release by the pancreas, endogenous glucose production (hepatic IR); whole-body glucose disposal and its main  components (i.e. glucose oxidation and glycogen synthesis; muscle IR); lipolysis and lipid oxidation (adipose tissue IR) (21). The mechanisms by which the majority of insulin-resistant individuals are protected from developing T2DM remain a mystery, but it is the inability of pancreatic b-cell to compensate for IR that renders individuals frankly diabetic. Fasting insulin secretion and total stimulated insulin output are increased as a result of the prevailing hyperglycaemia, and are correlated with IR in a positive fashion; in time, as hyperglycaemia
worsens total insulin output begins to decline (14, 22, 23). In NAFLD, a long-term increase in HGP can exacerbate fasting and post-prandial hyperglycaemia and predispose to T2DM development (13), although this does not explain the marked impairment in indices of dynamic b-cell responsiveness, such as glucose sensitivity. An alternate hypothesis is that the main cause of the IR, i.e. lipotoxicity, is also directly responsible for the b-cell failure (22). Many of the adverse effects of IR are secondary to compensatory hyperinsulinaemia acting on tissues/pathways that remain insulin sensitive, and much depends on the primary function of the organ/tissue involved (14). In the liver, hyperinsulinaemia stimulates the transcription factor Sterol Regulatory Element-Binding Protein-
1c (SREBP-1c), which activates most genes involved in DNL. The contribution of DNL to HFC,
which is less than 5% in healthy subjects, increases to approximately 25–30% in NAFLD (24). Hence, in this condition the compensatory hyperinsulinaemia and the increased delivery of NEFA turn the liver into a ‘fat producing factory’, starting a vicious cycle that worsens the atherogenic lipid profile and increases the likelihood of cardiovascular complications. Increased amounts of circulating and intracellular NEFA are also associated with an increase in nuclear factor kappa-b (NF-jB), leading to increased transcription of interleukin-6 and other proinflammatory cytokines (25). NAFLD, in particular nonalcoholic steatohepatitis (NASH), may also directly contribute to the low-grade inflammatory state of IR through the hepatic production of several inflammatory
mediators (e.g., C-reactive protein, fibrinogen, monocyte chemotactic protein 1, and tumour necrosis factora) (25), as well as other mediators potentially involved in the pathogenesis of metabolic alterations and cardiovascular disease, such as fibrinogen, betatrophin (ANGPTL8), Fibroblast growth factor (FGF)-21 and Fetuin A.
In this setting, the direct contribution of NAFLD to IR and MetS is tightly inter-related with that of VF. HFC and VF are highly correlated with each other and to the degree of IR, but the relative role of both fat depots on IR is controversial. The comparison of subjects with low VF and low HFC vs. subjects with both high VF and HFC yielded contrasting results (26, 27), but a recent analysis showed that having increased HFC with low VF is more deleterious than having high VF with low HFC (28). The portal theory suggests that VF may be harmful because omental and mesenteric adipocytes are more insulin-resistant and may release more NEFA into the portal vein than subcutaneous adipocytes (29). The direct impact of VF on glucose and lipid metabolism is, however, controversial. VF may also release more inflammatory cytokines than subcutaneous
fat and contribute to both systemic and hepatic inflammation (29). However, it is unlikely that FFAs released by VF are responsible for generalized lipotoxicity, except through cytokines released by the dysfunctional tissues (30). In fact, VF releases more pro-inflammatory cytokines than subcutaneous fat and contributes to both systemic and hepatic inflammation (29). Adiponectin,
the main adipokine with insulin-sensitizing, anti-inflammatory and anti-fibrotic action (31), may be also involved in the interplay between the liver and adipose tissue in NAFLD patients. Indeed, circulating adiponectin decreases with NAFLD severity (32), IR and adipose tissue inflammation, while experimental evidence suggests a protective role of this adipokine on HFC and liver disease progression (33).
The pattern of IR in patients with NAFLD described so far is quite different from that found in severe liver disease of any other etiology. In non-diabetic patients with cirrhosis, basal HGP is normal and suppressed by insulin; lipolysis is increased in the post-absorptive state because of ‘accelerated starvation’ observed in cirrhotic patients, but it is suppressed by insulin in an almost
normal manner. Additionally, hyperinsulinaemia in cirrhotic patients is mainly caused by hepatocellular dysfunction and intrahepatic shunting (34). The strong inter-relationship between NAFLD and IR suggests that NAFLD may be both a marker and a promoter of IR/hyperinsulinaemia. Beyond that, the presence of NAFLD may also differentiate those T2DM
patients who will develop specific metabolic and cardiovascular complications (35). However, NAFLD developing in individuals carrying strong genetic risk factors, such as in the presence of homozygosity for the rs738409 C>G variant in the Patatin-like phospholipase domain-containing protein 3 gene (PNPLA3 I148M variant) or associated with rare loss-of-function mutations in Apolipoprotein B (APOB), may be accompanied by less severe IR and fewer MetS features, although, as discussed later, a combination of obesity, IR and genetic risk factors is most frequently observed in clinical practice (13, 36). NAFLD as a cause of T2DM: the epidemiological evidence
Table 1 summarizes the principal data from observational cohort or case–control studies that have assessed the association between NAFLD, as detected by ultrasonography or computed tomography, and the risk of incident T2DM (37–53). The main characteristics of the study populations, the length of follow-up period, the diagnostic criteria used for NAFLD and T2DM, the relative risks of developing T2DM, and the list of covariates considered in multivariable regression models have been specified. We did not include the large number of prospective, population-based cohort studies that used serum liver enzyme levels (i.e. surrogate markers of NAFLD) to diagnose NAFLD. These studies have consistently shown that mildly elevated serum liver enzyme levels are associated with an increased risk of incident T2DM, independently of common risk factors in various ethnic populations (54). The vast majority of the published studies have shown that NAFLD diagnosed on ultrasonography substantially increased the risk of incident T2DM (Table 1). Only one retrospective cohort study did not find any significant association between NAFLD and the risk of T2DM after adjusting for confounding variables (37). The risk of incident T2DM varied markedly from a 33% (42) to a 5.5-fold increase in patients with NAFLD (39). This wide inter-study variability might reflect differences in the demographic characteristics of the study populations, in the length of follow-up period (ranging from a mean period of 3–12.8 years), the
varying degree of confounder adjustment, and differences in NAFLD severity (as detected either by
ultrasonography or non-invasive scoring systems of advanced hepatic fibrosis) in individual studies. For example, a large prospective cohort study of over 25 000 Korean non-diabetic middle-aged men demonstrated that NAFLD was an independent risk factor for incident T2DM, and that the absolute risk increased sharply with the ultrasonographic severity of NAFLD at baseline (absent: 7.0%, mild: 9.8%, moderate-to-severe: 17.8%). The hazard ratios for T2DM development were higher in subjects with mild steatosis (adjusted-HR 1.09, 95% CI 0.8–1.5) and in those with moderate-to-severe steatosis (adjusted-HR 1.73, 95% CI 1.0–3.0) compared to the normal group even after
adjusting for a wide range of T2DM risk factors (43). An independent retrospective study of an occupational cohort of 38 291 Korean individuals showed that the HRs for incident T2DM comparing NAFLD with low NAFLD fibrosis score (a reliable non-invasive marker of advanced liver fibrosis) and NAFLD with intermediate or high fibrosis score vs. the non-NAFLD group were 2.0 (95% CI 1.8–2.2) and 4.7 (95% CI 3.7–6.1) respectively (46). Interestingly, Fukuda et al. (49) examined the impact of NAFLD on the risk of incident T2DM in non-overweight individuals. Using a population-based retrospective cohort study of 4629 non-diabetic Japanese individuals enrolled in a health check-up program for more than 10 years, the authors found that the incidence
rates of T2DM were 3.2% in the non-overweight without NAFLD group, 14.4% in the non-overweight with NAFLD group, 8.0% in the overweight without NAFLD group and 26.4% in the overweight with NAFLD group respectively. The adjusted HR in the non-overweight with NAFLD group (HR 3.6, 95% CI 2.1–5.7) was higher than that in the overweight without NAFLD group (HR 2.0, 95% CI 1.5–2.7), or that in the non-overweight without NAFLD group (49).
Similarly, Sung et al. (44) have demonstrated in another occupational cohort study of over 12 000 Korean individuals that the clustering of IR (by homeostasis model assessment, HOMA-IR), overweight/obesity, and NAFLD (as detected by ultrasonography) was common and markedly increased the risk of incident T2DM. In the fully adjusted regression model, the HRs for incident
T2DM were 3.9 (95% CI 2.8–5.4) for HOMA-estimated insulin resistance, 1.6 (95% CI 1.2–2.2) for overweight/obesity and 2.4 (95% CI 1.7–3.4) for fatty liver. The HR for the presence of all three risk factors in the fully adjusted model was 14.1 (95% CI 8.9–22.2). Notably, in this same observational cohort, Sung et al. (47) have further assessed the risk of incident T2DM at 5 years of follow-up in the following three subgroups of subjects: (1) in those in whom there was resolution of NAFLD over 5 years; (2) in those in whom there was a development of new NAFLD between baseline and the follow-up examinations; and (3) in subjects in whom there was an increase in severity of NAFLD, from mild fatty liver noted at baseline to moderate-severe fatty liver, identified at follow-up examination.
Interestingly, these data showed that changing NAFLD status over a 5-year period was associated with markedly different risks of incident T2DM. In particular, the individuals in whom the severity of fatty liver worsened over time showed a marked increase in risk of incident T2DM compared with the risk in people with resolution of fatty liver. Conversely, there was a significant T2DM risk reduction in those individuals in whom NAFLD on ultrasonography resolved over time (47). Similarly, in a cohort of 4604 Japanese non-diabetic individuals who were followed up for a mean period of 11.3 years, Yamazaki et al. (48) reported that NAFLD at baseline was associated with an approximately 2.5-fold increased risk of incident T2DM, and that NAFLD improvement was associated with an approximately 70% risk reduction of developing T2DM, independently of common risk factors. However, it is important to note that these two studies are not interventional clinical trials (47, 48), so caution is needed in interpreting the data. Nevertheless, a recent systematic review and meta-analysis of 20 observational studies, involving more than 115 000
individuals, found that NAFLD (as diagnosed either by abnormal serum liver enzymes or by ultrasonography) was associated with an almost two-fold increased risk of incident T2DM over a median period of 5 years (54). Although it would seem that there are subsets of NAFLD patients, who have different levels of T2DM risk, there is to date only one small study also suggesting that the presence of biopsy-confirmed NASH was a stronger risk factor of T2DM than simple steatosis. In fact, in a retrospective cohort study of 129 Sweden adults with biopsy-proven NAFLD, Ekstedt et al. (55) found that 80% of these patients developed either new onset T2DM or pre-diabetes, and that patients with NASH had an approximately threefold higher risk of developing T2DM than those with simple steatosis over a mean follow-up of 14 years. This finding is consistent with the accepted notion that NASH patients tend to have a greater burden of metabolic diseases/T2DM, but
further studies in larger cohorts of patients with biopsy confirmed NAFLD are required to elucidate whether the severity of NAFLD histology may differentially affect T2DM development.
Collectively, although there is now substantial evidence that NAFLD is strongly associated with incident T2DM, risk and there is emerging evidence that this risk varies according to the severity of NAFLD, further evidence is unquestionably needed, especially in non-Asian populations, as nearly all of the studies reported in Table 1 – except for the recent study by Shah et al. –have been conducted in various Asian populations. This finding might be important because the anthropometric phenotypes and diets in Asian countries are very different from those in Western countries. However, several population-based studies, involving American and European individuals, have reported that mildly elevated serum liver enzymes are independent, long-term
predictors of new-onset T2DM (50). Some other caveats to keep in mind are that in none of the published studies, with two exceptions (35, 47), T2DM diagnosis was based on 2-h post-load plasma glucose levels, and that the adjustment for potential confounding variables was not always complete. For example, data on waist circumference was often not reported, and family history of T2DM, physical activity level or IR markers were not always included in multivariable
regression models. Prospective studies with a larger panel of known risk factors for T2DM (including genetic variants) are required to firmly establish an independent contribution of NAFLD to new-onset T2DM. Finally, controlled intervention trials will be necessary to determine whether treating NAFLD/NASH leads to T2DM risk reduction.
Molecular features of NAFLD-related hepatic IR Hepatic IR is responsible for the increased gluconeogenesis and HGP that predispose to T2DM development (see above), and is associated with HFC. As alluded to earlier, HFC is determined by the balance of extrinsic (gastrointestinal lipid absorption, adipose lipolysis), and intrinsic pathways – DNL, fatty acid oxidation and TG
secretion as VLDL (56). As the most parsimonious explanation for a shared genetic or environmental determinant of NAFLD and IR is a cell-autonomous pathway, we focus this section on hepatocyte-specific pathways. Of these, DNL accounts for as much as 30% of HFC in the obese/insulin-resistant patient and thus becomes an attractive etiological possibility for NAFLD-related IR. In fact, hepatic insulin signalling is intimately tied with the molecular machinery that determines DNL (57), i.e. the production of long-chain fatty acids from two-carbon precursors through sequential action of Acetyl CoA Carboxylase (ACC) and Fatty Acid Synthase (FAS), followed by various fatty acid elongases and desaturases (58). Many of these enzymes are under
direct, albeit not exclusive, transcriptional control of SREBP-1c, which has the well-earned title of master regulator of DNL and led to search for mechanistic determinants of SREBP-1c function. SREBP-1c itself is regulated by fasting/refeeding, through hormonal action of insulin and glucagon (59), although the specific pathways downstream of these hormones remain under active debate. The most compelling evidence from this line of research implicates insulin-mediated activation
of the mechanistic target of rapamycin (mTOR), an evolutionarily conserved serine-threonine kinase that links nutrient state to cellular growth. For instance, mice with liver-specific ablation of the mTOR complex 1 (mTORC1)-defining subunit Raptor show reduced DNL, and are thus protected from high-fat diet-induced fatty liver (60). Consistently, inhibition of mTOR/RAPTOR
interaction with rapamycin blocks insulin-dependent SREBP-1c activation in primary rat hepatocytes and liver (61–63), leading to the widely accepted ‘bifurcation model’ whereby mTORC1 is required for the lipogenic actions of insulin. Interestingly, mice lacking hepatocyte Tuberous sclerosis complex-1 (TSC1), the endogenous inhibitor of mTORC1, also escape diet-induced fatty liver due to reduced AKT and SREBP-1c action (63, 64). AKT is a critical mediator of insulin signal transduction (63–65), and mice lacking both hepatic isoforms (L-Akt1:Akt2) show defects in feeding-induced SREBP-1c expression, similar to mice lacking hepatic insulin receptor (INSR) (57, 66). L-Akt1:Akt2 mice also show marked glucose intolerance (57, 66), likely due to loss of its inhibitory action on Forkhead O transcription factor-1 (FOXO1) (67). FOXO1, a member of the FOXO family of transcription factors, is necessary for insulin suppression of HGP. Physiological insulin levels prompt AKT mediated FOXO1 phosphorylation, leading to rapid FOXO1 nuclear exclusion and degradation (68, 69). In the absence of insulin signalling, FOXOs are transcriptionally active. In hepatocytes, the most consistently observed FOXO1-induced response has been activation of Glucose-6-phosphatase (G6PC) expression (70, 71) in response to binding to conserved insulin-regulatory sequences in the G6PC promoter sequence (72) coordinately with NOTCH proteins (73). Although the bulk of FOXO studies in liver have thus justifiably focused on
its role in HGP, a parallel and consistent role in regulation of HFC has also emerged. Liver-specific ablation of FOXO1 is associated with increased HFC (74, 75), an effect exacerbated by simultaneous excision of all hepatic FOXOs and high-fat diet feeding (76). Expectedly, excess HFC in FOXO null animals is secondary to a cell autonomous increase in DNL (76, 77), but the molecular mechanism underlying this reproducible finding is still debate. It is likely that excess DNL may be the endresult of multiple, simultaneous processes, as FOXO deficient hepatocytes show disrupted autophagy (78) and altered NAD+ levels (76). However, an alternative hypothesis has emerged that an altered substrate flux due to unbalanced action of both G6PC, mediating
glucose release from hepatocytes into the circulation (decreased), and glucokinase (GCK), which facilitates glucose entry from the extracellular space and supports DNL (increased), may cause the excess HFC in FOXO null animals (77). This finding would be consistent with the on-target hepatic steatosis seen with administration of GCK activators (79, 80), while remaining are consistent with the bifurcation model of hepatic insulin action on DNL and HGP (64).
Great progress has been made in identifying upstream AKT activators and downstream targets (81,
82), but mechanisms underlying the termination of the AKT signal have been understudied until the discovery of the Pleckstrin homology (PH) domain leucine-rich repeat protein phosphatase (PHLPP) gene family (83, 84). PHLPPs were first shown to slow AKT-dependent cancer progression by dephosphorylating AKT at Ser473 (85–88), and have recently been proven to impact obesity-related metabolic disease. Obese mice show a loss of PHLPP2 stability, leading to an inability to ‘terminate’ AKT signalling – this causes a prolongation of insulin action – and secondary induction of SREBP-1c, an effect that can be reversed by adenoviral PHLPP2 expression
(89). Consistently, knockdown of PHLPP2 in lean mice causes AKT hyperactivity, excess DNL and fatty liver (89), similar to mice with constitutive active induction of AKT activity (90–92), suggesting that endogenous PHLPP2 activity is required to terminate AKT signaling and avoid excessive lipogenesis. In combination with data from liver-specific RICTOR knockout mice (92),
which are unable to maximally activate AKT due to the inability to phosphorylate ALT at Ser473, and show consequent glucose intolerance but reduced HFC, a revised ‘bifurcation’ model has emerged whereby AKT must be activated to inhibit FOXO-induced HGP, but also inactivated in a timely fashion to avoid excess DNL (Fig. 1). Of note, in almost all of the above mouse models,
discordance was detected between DNL and HGP, and thus between HFC and circulating glucose levels. Disruption of canonical insulin signaling by means of ablation of INSR (57), IRS (93) or AKT (94), leads to increased HGP, but reduced DNL. Increased ‘late’ AKT activity by means of altered PHLPP2, or reduced mTORC1 function by ablation of RAPTOR, reduces DNL, without changes to HGP. Ablation of the key regulator of insulin-regulated HGP, FOXO, increased DNL. These loss-of-function mouse models are obviously extreme examples, with complete absence of critical signalling components, and moderate down-regulation of hepatic INSR expression, which is
associated with preserved regulation of glucose metabolism but increased cell-autonomous DNL, may better recapitulate human NAFLD and T2DM (95). In sum, however, data from these genetically manipulated mice do not support a role of hepatic DNL as a primary determinant of hepatic IR. These data are echoed by mouse models of diet-induced NASH, methionine/choline-
deficient diet (MCDD)-feeding. MCDD-fed mice develop macrovesicular steatosis, lobular inflammation and fibrosis (96), but tend to lose body weight and, as such, are more insulin-sensitive than control animals (97), proving that excess HFC alone is insufficient to induce glucose intolerance. Of course, this does not rule out the potential contribution of excess hepatic DAG/
ceramides to exacerbate systemic glucose homeostasis, or cell non-autonomous effects, as discussed earlier. The key molecular features of unbalanced activation of hepatic insulin signalling pathways have been confirmed in clinical samples of patients (12). Decreased expression of INSR protein has indeed been observed in the liver of patients with NAFLD. Consistently, despite compensatory hyperinsulinaemia, decreased INSR expression was accompanied by reduced phosphorylation status of AKT1 and increased FOXO1 activity (98, 99).
In the liver of patients with NAFLD, reduced insulin signalling through AKT1 has been associated with both enhanced oxidative stress (98) and increased DAG concentrations, leading to activation of atypical protein kinase C isoforms (e.g., PKCe) able to contrast insulin signalling (100). However, recent association studies and experimental data point to C:16-ceramides (101, 102) and possibly lyso-phosphatidyl-cholines (103, 104) as important lipid mediators of hepatic IR in NAFLD.
While insulin ability to restrain HGP is impaired in NAFLD, it has been observed that FOXO1-dependent IRS2 is up-regulated with preservation of the activation status of AKT2 and of induction of SREBP-1c and lipogenic pathways (99). The substrate for DNL was linked to induction of GCK by SREBP-1c (105), parallelingincreasing HFC (99, 106). In patients with NASH, this was accompanied by activation of NOTCH signalling, which correlated with the severity of hepatic steatosis, IR and gluconeogenesis (107).
NAFLD as a consequence of IR and T2DM: lesson from genetic studies During the last years, genome wide association studies revealed the major genetic loci, whose common variants
predispose to NAFLD (108). We believe that this information will prove helpful in disentangling the complex link between HFC and T2DM. According to a simple syllogism, if a genetic risk variant causes NAFLD and NAFLD causes T2DM, then this genetic variant must also cause T2DM with a comparable effect size. Indeed, in the case of validated germline genetic variants with a proven causal role in NAFLD, reverse causation (because they are inherited and cannot be modified) and confounding factors (because they are randomly inherited from the parents) cannot bias the association with the risk of IR and T2DM. This is the principle underpinning Mendelian randomization analysis, which is used to dissect possible causal relationships in association studies (Fig. 2).
The major common genetic risk variant for NAFLD is undoubtedly represented by the I148M variant in the PNPLA3 gene (109, 110), which is carried by one in three individuals in the general population and by one in two patients with NAFLD. The PNPLA3 protein is a lipase that hydrolyses triglycerides in hepatocytes and retinyl-esters in hepatic stellate cells, and is thus
involved in the regulation of lipid metabolism and several cell functions. The I148M loss-of-function variant predisposes to increased HFC and progressive liver disease in the presence of environmental ‘stressors’, such asIR (111–113). The underlying mechanisms are still under debate, but likely involve accumulation of the 148M protein variant on the surface of lipid droplets, hindering access to other lipases, resulting in altered TG remodelling and retinol release (111, 114–116), and influencing hepatic and circulating lipid profile (101, 117, 118). However, despite its large effect on HFC, the I148M variant does not seem to markedly impact on systemic/hepatic IR, NEFA levels, or the risk of T2DM (109, 110). Carriers of the I148M variant may have a small increase in T2DM risk, mainly in severely obese patients (119). However, this marginal effect is much smaller than the expected impact of increased HFC and is possibly mediated by predisposition to more severe liver disease in these patients. This is not a unique example. The Transmembrane 6 Superfamily Member 2 (TM6SF2) rs58542926 C>T E167K variant has more recently been associated with NAFLD (10, 120). In this case, the mechanism is likely to be related to hepatocellular retention of lipids due to altered lipidation of nascent VLDL (10, 120–123). Similar to PNPLA3 I148M, the E167K variant does not alter T2DM risk (124). Similarly, the Membrane-bound OAcyl Transferase protein 7 (MBOAT7) rs641738 C>T gene variant, which regulates arachidonoyl-phosphatidyl-inositol metabolism, and circulating phosphatidylinositol
composition, has now been associated with NAFLD development and progression, without any significant impact on T2DM prevalence (125). Another validated locus influencing NAFLD risk is
the Glucokinase regulator (GCKR) gene (126–128). The common P446L variant seems to predispose to increased HFC by deregulation of glucose uptake and DNL in hepatocytes. In the presence of the P446L variant, compartmentalization of energy as liver TG synthesized from circulating glucose favours liver damage, but protects from T2DM development (126, 129, 130).
Since GCKR directly influences glucose metabolism, this cannot be generalized to conclude that increased ability to store energy as TG in the liver protects from hyperglycaemia, and future studies evaluating comprehensive genetic risk scores will be needed to better clarify this issue. Furthermore, it cannot yet be ruled out that different forms of NAFLD characterized by accumulation of specific lipids favouring IR, such as ceramides, may cause T2DM (101).
Rare loss-of-function variants in APOB responsible for familial hypobetalipoproteinaemia (FHBL) provide the clearest example of the dissociation between HFC and IR, and underscore the independent effect of severe HFC on liver disease progression (131). FHBL is indeed associated with severe steatosis due to defective export of lipids from hepatocytes by VLDL (which requires
ApoB100 protein for correct secretion), progressive fibrosis and hepatocellular carcinoma (131, 132). However, FHBL is neither associated with systemic and hepatic IR, nor with increased NEFA flux to the liver, nor with T2DM (36, 131–133). Therefore, although organ-specific deposition of fat
is a strong predictor of IR, HFC per se does not invariably result in IR and T2DM (as summarized in Table 2), but in progressive NAFLD, which suggests that NAFLD may be a frequent consequence rather than a cause of IR and T2DM, or that progressive NAFLD and T2DM may
represent two different outcomes stemming from IR (see below). In keeping with this view, genetic variants that impair hepatic insulin signalling have been associated with hepatic fibrosis, as if IR favors progressive NAFLD (134). Consistently, a new therapeutic approach with the new farnesoid X receptor (FXR) agonist, obeticholic acid, reduced both HFC and liver damage in patients with NASH, but it was associated with worsening of IR (135).
A unifying hypothesis Insulin resistance, compensatory hyperinsulinaemia and visceral obesity contribute to the development of NAFLD first; in return, the insulin resistant fatty liver overproduces glucose and VLDL thus boosting the mechanisms that lead to with progressive exhaustion of pancreatic b cell reserve, leading to T2DM development at later stages of life. This finding would explain the epidemiological observations of a strong association between the presence and severity of NAFLD and the risk of developing incident T2DM, without implying that HFC per se plays a causal role. In this context energy storage under as TG in lipid droplets in hepatocytes may be considered as an attempt to protect the liver from lipotoxicity induced by NEFA and from hyperinsulinaemia-driven DNL, and subjects who display a better ability to clear fat from the liver would probably be those at lower risk of developing long-term hepatic complications. At the same time, systemic IR and hypo-adiponectinaemia may contribute to the development of both hepatic IR and T2DM, as adiponectin receptors have ceramidase activity (136). A working model for the hypothesized mechanisms leading from IR/MetS to parallel NAFLD and to T2DM pathogenesis is presented in Figure 3. The practical implications of this model are the following: (a) HFC is strongly linked with metabolic derangements, independently of many common and measurable risk factors, and thus represents an excellent marker of incident T2DM risk (at least in patients without strong coexisting genetic risk factors for NAFLD); (b) research attention should focus on specific lipid species favouring hepatic IR rather than on the amount of HFC per se; and (c) novel therapeutic approaches for T2DM should be aimed to decrease these specific lipid species. Indeed, DNL inhibition and steatosis reduction might benefit liver disease progression, but may worsen glycaemic control. However, further prospective and mechanistic studies are needed to better elucidate these fascinating issues.

Conclusions. It has become increasingly clear that there are complicated, bidirectional links between NAFLD and T2DM. These two diseases share many aspects of their pathophysiology, and although IR is at the centre of both, growing evidence suggests divergent pathogenic effects of IR on NAFLD and T2DM. However, many aspects of the close interactions between NAFLD and IR/T2DM are not yet fully elucidated yet, as genetic risk factors for increased HFC have revealed that there is a disconnection between these two conditions. We believe that a closer focus on the mechanisms that underlie these observations will identify new therapeutic targets not only for liver disease, but also for T2DM and other metabolic diseases.
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Figures legend
Fig. 1. Revised mechanism underlying the ‘bifurcation’ of hepatocyte insulin signalling underpinning the pathogenesis of progressive NAFLD (increased hepatic lipogenesis) and type 2 diabetes (increased hepatic glucose production). FOXOs, forkhead box O transcription factors; INSR, insulin receptor; IRS, insulin receptor substrate; mTORC, mammalian target of rapamycin; PHLPP2, pleckstrin homology domain leucine-rich repeat protein phosphatase 2; PI3, inositol-3-phosphate; SREBP-1c, sterol regulatory element binding protein-1c.


Fig. 2. Mendelian randomization for determining the risk of insulin resistance and type 2 diabetes related to NAFLD: a qualitative approach. Mendelian randomization is an instrumental variable
approach to infer causality in association studies in the presence of potential confounding and reverse causation. The modifiable exposure in this case is hepatic fat content. Genetic risk variants for NAFLD are used as the instrument. Causal effects of hepatic fat content on insulin resistance (IR) and type 2 diabetes (T2DM) are estimated by examining the genetic risk variants for association with hepatic fat content, as well as with IR/T2DM using a triangulation approach. The association between hepatic fat content and IR/T2DM can arise from both directions. However, as genetic risk factors are strongly associated with hepatic fat content, but there is no predisposing effect on IR/T2DM risk, we might conclude that hepatic fat content does not directly cause IR/T2DM, but the opposite should held true. This does not exclude that NAFLD may be caused
exclusively by strong genetic or other non-genetic factors independently of coexisting IR/T2DM.
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